XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Business Combination | 3 Months Ended
--- | ---
Mar. 31, 2024
Business Combination |
Business Combination | Note 3. Business Combination On January 9, 2023, the Company completed the acquisition of Old Catheter for the purpose of acquiring Old Catheter’s existing and developing product lines based on unique electrophysiology technology. Pursuant to the Merger Agreement, all Old Catheter common stock shares issued and outstanding and convertible promissory notes, representing an aggregate principal of $25.2 million, were converted into a right to receive 14,649.592 shares of a new class of the Company’s preferred stock, designated Series X Convertible Preferred Stock. Additionally, all outstanding stock options to purchase Old Catheter common stock were assumed and converted into options to purchase approximately 753,699 shares of the Company's common stock. The total purchase consideration for the Merger was $72.5 million which represents the sum of the (i) estimated fair value of the 14,649.592 Series X Convertible Preferred Stock issued and (ii) the portion of the estimated fair value of $3.4 million representing the Company stock options issued in replacement of Old Catheter share-based payment awards as required under FASB Topic 805, Business Combinations ("Topic 805"). The fair value of the Series X Convertible Preferred Stock includes certain discounts applied to the closing stock price of the Company, on January 9, 2023, of $6.09 per share. The following table summarizes the fair value of the consideration associated with the Merger ($ in thousands):
Description |  | Fair Value as of January 9, 2023 |
Fair value of 14,649.592 Series X convertible preferred stock issued |  | $ | 69,140 |
Fair value of Old Catheter’s fully vested stock options |  |  | 3,404 |
Total Purchase Price |  | $ | 72,544 |
The Merger was accounted for as a business combination in accordance with Topic 805, and the Company has been determined to be the accounting acquirer. The Company allocated the purchase price to the assets acquired and liabilities assumed at fair value. The preliminary purchase price allocation reflects various preliminary fair value estimates and analyses, including certain tangible assets acquired and liabilities assumed, the valuation of intangible assets acquired, liabilities assumed, and goodwill, which were subject to change within the measurement period as preliminary valuations were being finalized (generally one year from the acquisition date). Measurement period adjustments were recorded in the reporting period in which the estimates are finalized, and adjustment amounts were determined. During the three months ended June 30, 2023, the Company recorded measurement period adjustments based on changes to certain estimates and assumptions and their related impact to the purchase price allocation. Developed technology was revised from $35.1 million to $27.0 million; trademarks were revised from $1.7 million to $1.3 million; customer relationships were revised from $220 thousand to $62 thousand; goodwill was revised from $56.0 million to $60.9 million; and royalties payable were revised from $7.6 million to $14.2 million. The following table summarizes the final purchase price allocations relating to the Merger ($ in thousands):
Description |  | Fair Value |
Assets acquired: |  |  |
Cash and cash equivalents |  | $ | 15 |
Accounts receivable |  |  | 71 |
Inventories |  |  | 52 |
Prepaid expenses and other current assets |  |  | 23 |
Property and equipment, net |  |  | 26 |
Lease right-of-use assets |  |  | 119 |
Other assets |  |  | 8 |
Developed technology |  |  | 27,014 |
Customer relationships |  |  | 62 |
Trademarks |  |  | 1,285 |
Goodwill |  |  | 60,934 |
Total assets acquired |  | $ | 89,609 |
Liabilities assumed: |  |  |  |
Accounts payable |  | $ | 922 |
Accrued expenses |  |  | 1,389 |
Lease liability |  |  | 124 |
Interest payable |  |  | 198 |
Convertible promissory notes |  |  | 250 |
Royalties payable |  |  | 14,182 |
Total liabilities assumed |  |  | 17,065 |
Total purchase price |  | $ | 72,544 |
All intangible assets acquired are subject to amortization and their associated acquisition date fair values and useful lives are as follows:
Intangible Assets |  | Fair Value |  |  | Useful Life |
Developed technology- VIVO |  | $ | 8,244 |  |  |  | 15 |
Developed technology- LockeT |  |  | 18,770 |  |  |  | 14 |
Customer relationships |  |  | 62 |  |  |  | 6 |
Trademark- VIVO |  |  | 876 |  |  |  | 9 |
Trademark- LockeT |  |  | 409 |  |  |  | 9 |
|  | $ | 28,361 |  |  |  |  |
Notwithstanding the above, as described in Note 7, management determined that there were indicators of asset impairment during the three months ended March 31, 2023, and assessed the carrying values of the Company’s intangible assets and goodwill. As a result, the Company recorded an impairment charge relating to goodwill of $56.1 million during the three months ended March 31, 2023. This amount represented the preliminary purchase price amount ascribed to goodwill. Transaction costs incurred in connection with this business combination amounted to approximately $1.7 million during the three months ended March 31, 2023. Pro Forma Financial Information The following table represents the revenue, net loss and net loss per share effect of the acquired company, as reported on a pro forma basis as if the acquisition occurred on January 1, 2023. These pro forma results are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the first day of the period presented, nor does the pro forma financial information purport to represent the results of operations for future periods. The following information for the three months ended March 31, 2023 is presented in thousands except for the per share data ($ in thousands, except per share data):
|  | Three Months Ended March 31, |
|  | 2023 |
Revenues |  | $ | 88 |
Net loss |  | $ | (66,570 | )
Net loss attributable to common stockholders |  | $ | (67,370 | )
Basic and diluted net loss per share – on a pro forma basis |  | $ | (13.56 | )

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//805/tableOfContent + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration